Pacific Biosciences Of California (PACB) Net Margin (2010 - 2026)

Pacific Biosciences Of California's Net Margin history runs 17 years deep, the most recent figure standing at 22.26% for Q1 2026.

• On a quarterly basis, Net Margin rose 112455.0% year-over-year to 22.26% in Q1 2026; TTM through Mar 2026 was 80.34%, a 35137.0% increase from a year earlier, with the FY2025 full-year figure at 341.47%, down 14029.0% from the prior year.
• Net Margin improved to 22.26% in Q1 2026 per PACB's latest filing, from 90.43% in the prior quarter.
• Across five years, Net Margin topped out at 6.04% in Q4 2024 and bottomed at 1146.81% in Q1 2025.
• The 5-year median for Net Margin is 151.94% (2024), against an average of 230.57%.
• Across the five-year window, Net Margin plunged 94537 bps in 2025 and surged 112455 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 308.5% in 2022, then jumped by 54 bps to 140.55% in 2023, then surged by 104 bps to 6.04% in 2024, then tumbled by 1596 bps to 90.43% in 2025, then surged by 75 bps to 22.26% in 2026.
• Per Business Quant, the three latest PACB Net Margin figures stand at 22.26% (Q1 2026), 90.43% (Q4 2025), and 98.85% (Q3 2025).